Search Results for "donepezil"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for donepezil. Results 1 to 10 of 15 total matches.
See also: Aricept
Donepezil (Aricept) for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • Jun 06, 1997 (Issue 1002)
Donepezil (Aricept) for Alzheimer's Disease ...
Donepezil hydrochloride (Aricept - Eisai), a piperidine-based acetylcholinesterase inhibitor, is now being marketed for oral treatment of cognitive symptoms in patients with mild to moderate dementia due to Alzheimer's disease. Donepezil is the second drug approved for this indication; tacrine hydrochloride (Cognex), also an acetylcholinesterase inhibitor, has been available in the USA for four years (Medical Letter, 35:87, 1993).
A Donepezil Patch (Adlarity) for Alzheimer's Disease (online only)
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022 (Issue 1656)
A Donepezil Patch (Adlarity) for Alzheimer's Disease (online only) ...
A once-weekly transdermal formulation of the
acetylcholinesterase inhibitor donepezil (Adlarity –
Corium) has been approved by the FDA for
treatment of mild, moderate, and severe Alzheimer's
disease (AD) dementia. Donepezil is the second
acetylcholinesterase inhibitor to become available in
a transdermal formulation; transdermal rivastigmine
(Exelon Patch), which is applied once daily, has been
available for years for the same indication. Donepezil
is also available in oral formulations (Aricept, and
generics) for treatment of AD dementia.
Namzaric - A Combination of 2 Old Drugs for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • Jul 20, 2015 (Issue 1473)
combination of extended-release (ER)
memantine (Namenda XR), an NMDA-receptor
antagonist, and donepezil ...
The FDA has approved Namzaric (Forest), a fixed-dose
combination of extended-release (ER)
memantine (Namenda XR), an NMDA-receptor
antagonist, and donepezil (Aricept, and generics),
an acetylcholinesterase inhibitor, for treatment of
moderate to severe Alzheimer's type dementia in
patients previously stabilized on both drugs. The
patent for Namenda has recently expired and generic
formulations of memantine 5- and 10-mg tablets have
been approved.
Drugs for Cognitive Loss and Dementia
The Medical Letter on Drugs and Therapeutics • Aug 22, 2022 (Issue 1657)
.2
Donepezil, galantamine, and rivastigmine are FDA approved
for treatment of AD dementia based ...
Alzheimer's disease (AD) is the most common
cause of dementia, but cognitive decline is also
associated with other neurological conditions such
as Parkinson's disease, dementia with Lewy bodies,
vascular dementia, and frontotemporal dementia.
Rivastigmine (Exelon) For Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • Oct 02, 2000 (Issue 1089)
for this indication; tacrine hydrochloride (Cognex) and donepezil hydrochloride (Aricept) are also available
(Medical ...
Rivastigmine tartrate (Exelon - Novartis), a carbamate-based cholinesterase inhibitor, is now being marketed for treatment of patients with dementia due to Alzheimer's disease.
Comparison Table: Drugs for Alzheimer's Disease (online only)
The Medical Letter on Drugs and Therapeutics • Aug 22, 2022 (Issue 1657)
Effects Drug Interactions Comments
Acetylcholinesterase Inhibitors
Donepezil – generic
Aricept (Eisai ...
View the Comparison Table: Drugs for Alzheimer's Disease
Galantamine (Reminyl) for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • Jun 25, 2001 (Issue 1107)
INHIBITORS FOR ALZHEIMER’S DISEASE
Drug Dosage Cost*
Donepezil − Aricept (Pfizer) 5 or 10 mg once/day ...
Galantamine hydrobromide (Reminyl), a tertiary alkaloid and phenanthrene derivative extracted from daffodil bulbs, is now being marketed for oral treatment of mild to moderate Alzheimer's disease. Galantamine is the fourth acetylcholinesterase inhibitor approved for this indication.
Table: Mechanisms of Drug Interactions (online only)
The Medical Letter on Drugs and Therapeutics • Sep 24, 2018 (Issue 1556)
penetration of the aminoglycoside
Antagonism Opioid + naloxone
Donepezil + an anticholinergic
Competitive ...
View Table: Mechanisms of Drug Interactions
Memantine for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • Sep 15, 2003 (Issue 1165)
inhibitors donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and tacrine (Cognex ...
Memantine hydrochloride, which has been used to treat dementia in Germany (Axura Merz) since 1982, has become the latest word-of-mouth miracle drug for Alzheimer's disease in the US (G Kolata, NY Times, June 15, 2003). Forest Laboratories has submitted a New Drug Application to the FDA for memantine. This review describes the standard treatment for Alzheimer's Disease, mechanism of action, clinical studies, adverse effects and dosage. Also included are sections on availability of the drug and how some people are obtaining memantine from abroad.
Aducanumab (Aduhelm) for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • Jul 12, 2021 (Issue 1628)
— The acetylcholinesterase
inhibitors donepezil, rivastigmine, and galantamine
and the NMDA-receptor antagonist memantine ...
Aducanumab-avwa (Aduhelm – Biogen/Eisai), an
IV amyloid beta-directed monoclonal antibody,
has received accelerated approval from the FDA
for treatment of Alzheimer's disease. The approval
was based on the surrogate endpoint of reduction in
amyloid beta plaques in the brain. The manufacturer
is required to conduct an additional randomized
controlled trial to establish that reducing amyloid
beta plaques with aducanumab improves clinical
outcomes in patients with Alzheimer's disease.